Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Context Safe and effective strategies to curb rising obesity prevalence rates are urgently needed and medications may play a more prominent role in future therapeutic regimens. Objective To review systematically the long-term efficacy and safety of approved antiobesity medications. Data sources MEDLINE, EMBASE, the Cochrane Controlled Trials Register, Current Science Meta-register of Controlled Trials, and reference lists of original studies and reviews were searched. Drug manufacturers and two obesity experts were contacted. No language restrictions were imposed. Study selection Double-blind, randomized controlled studies of approved antiobesity medications with follow-up periods of 1 y or greater were eligible for inclusion. Data extraction Two reviewers independently assessed all potentially relevant studies for inclusion and methodological quality using standardized abstraction forms. Results A total of 11orlistat (n=6021) and three sibutramine (n=929) studies met inclusion criteria. Attrition rates averaged 33% in orlistat studies and 48% in sibutramine studies. A random effects model was used for meta-analysis. Compared to placebo, orlistat-treated patients displayed a 2.7 kg (95% CI: 2.3-3.1 kg) or 2.9% (95% CI: 2.3-3.4%) greater reduction in weight and patients on sibutramine displayed a 4.3 kg (95% CI: 3.6-4.9 kg) or 4.6% (95% CI: 3.8-5.4%) greater weight reduction after 1 y of follow-up. The number of patients achieving 10% or greater weight loss was 12% (95% CI: 8-…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A pancreatic lipase inhibitor, orlistat blocks dietary fat absorption, resulting in ~3–5% weight loss.”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [57]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Prevalence and trends in obesity among US adults, 1999–2000
Flegal, K. M. (2002) · JAMA · doi:10.1001/jama.288.14.1723 · Cited by 6,190
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Prevalence and Trends in Overweight Among US Children and Adolescents, 1999-2000
Ogden, C. L. (2002) · JAMA · doi:10.1001/jama.288.14.1728 · Cited by 4,060
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults
Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath, C. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910073411501 · Cited by 3,643
Cited by
Items 101–200 of 351
Role of Vitamin B12 and Folate in Metabolic Syndrome
Ashok, T., Puttam, H., Tarnate, V. C. A., Jhaveri, S., Avanthika, C., Treviño, A. G. T., Sandeep, S. L., & Ahmed, N. (2021) · Cureus · doi:10.7759/cureus.18521 · Cited by 60
Enkhmaa, B., Surampudi, P. N., Anuurad, E., & Berglund, L. (2015) · Europe PMC (PubMed Central) · Cited by 65
Atkinson, T. J. (2008) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00412.x · Cited by 49
“In terms of side effects, sibutramine mainly causes dry mouth (79) but is also associated with hypertension and increased pulse rate (77); orlistat mainly causes unpleasant gastrointestinal side effects (e.”
InfluentialThe Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
Pi-Sunyer, F. X. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.07.1785 · Cited by 49
POSTON, W. S. C., HADDOCK, C. K., PINKSTON, M. M., PACE, P., REEVES, R. S., KARAKOC, N., JONES, P., & FOREYT, J. P. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01702.x · Cited by 46
Pharmacotherapeutic Options for Overweight Adolescents
Dunican, K. C., Desilets, A. R., & Montalbano, J. K. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k022 · Cited by 53
Pharmacotherapy for the treatment of obesity
Sweeting, A., HOCKING, S. L., & Markovic, T. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.005 · Cited by 53
Medications as Adjunct Therapy for Weight Loss: Approved and Off-Label Agents in Use
Moyers, S. B. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2005.03.010 · Cited by 56
Waterlander, W., Whittaker, R., McRobbie, H., Dorey, E., Ball, K., Maddison, R., Myers Smith, K., Crawford, D., Jiang, Y., Gu, Y., et al. (2014) · JMIR mhealth and uhealth · doi:10.2196/mhealth.2850 · Cited by 43
Sibutramine and the management of obesity
Poston, W. S. C., & Foreyt, J. P. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.3.633 · Cited by 41
Weight management in primary care: how can it be made more effective?
Maryon‐Davis, A. (2005) · Proceedings of The Nutrition Society · doi:10.1079/pns2004414 · Cited by 46
The risk of anal incontinence in obese women
Altman, D., Falconer, C., Rössner, S., & Melin, I. (2007) · International Urogynecology Journal · doi:10.1007/s00192-007-0341-9 · Cited by 40
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“It is still available, but its use is limited by gastrointestinal side effects (e.g., steatorrhea, fecal incontinence) and poor long-term adherence [57].”
Features of Polycystic Ovary Syndrome in adolescence.
Tsikouras, P. N., Liatsikos, S. A., Manav, B., Zervoudis, S., Poiană, C., Nikolaos, T. P., Petros, P., Dimitraki, M., Koukouli, C., Galazios, G. C., et al. (2015) · PubMed Central · Cited by 52
Implications of Gene–Behavior Interactions: Prevention and Intervention for Obesity
Bray, M. S. (2008) · Obesity · doi:10.1038/oby.2008.522 · Cited by 40
Neural and humoral changes associated with the adjustable gastric band: insights from a rodent model
Kampe, J., Stefanidis, A., Lockie, S. H., Brown, W. A., Dixon, J. B., Odoi, A., Spencer, S. J., Raven, J., & Oldfield, B. J. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.25 · Cited by 36
Cost-Effectiveness Analysis of Qsymia for Weight Loss
Finkelstein, E. A., Kruger, E., & Karnawat, S. (2015) · PharmacoEconomics · doi:10.1007/s40273-014-0182-6 · Cited by 34
Pharmacotherapy of Obesity: Limits and Perspectives
Rosa-Gonçalves, P., & Majerowicz, D. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00328-6 · Cited by 34
Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK
Beard, S. M., McCrink, L., Le, T. K., Garcia-Cebrian, A., Monz, B. U., & Malik, R. A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x253852 · Cited by 34
Drug Insight: appetite suppressants
Bray, G. A. (2005) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0092 · Cited by 35
Yoong, S. L., Carey, M. L., Sanson‐Fisher, R., & D’Este, C. A. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-48 · Cited by 33
A Mindfulness-Based Health Wellness Program for Individuals With Prader-Willi Syndrome
Singh, N. N., Lancioni, G. E., Singh, A. N. A., Winton, A. S. W., Singh, A. D. A., & Singh, J. (2011) · Journal of Mental Health Research in Intellectual Disabilities · doi:10.1080/19315864.2011.583489 · Cited by 34
Cost-Effectiveness of Pharmacotherapy to Reduce Obesity
Veerman, L. J., Barendregt, J. J., Forster, M., & Vos, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026051 · Cited by 36
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Taking Orlistat: Predicting Weight Loss over 6 Months
Hollywood, A., & Ogden, J. (2011) · Journal of Obesity · doi:10.1155/2011/806896 · Cited by 28
“glycemic control when compared to placebo [4].”
BackgroundResultInfluentialNPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine
Erondu, N., Addy, C., Lu, K., Mallick, M., Musser, B. J., Gantz, I., Proietto, J., Astrup, A. V., Toubro, S., Rissannen, A. M., et al. (2007) · Obesity · doi:10.1038/oby.2007.242 · Cited by 30
A Mindfulness-Based Health Wellness Program for Managing Morbid Obesity
Singh, N. N., Lancioni, G. E., Singh, A. N. A., Winton, A. S. W., Singh, J., McAleavey, K., Adkins, A. D., & Joy, S. D. S. (2008) · Clinical Case Studies · doi:10.1177/1534650107312869 · Cited by 34
Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Caterson, I. D., Sweeting, A., Tabet, E. J., & Markovic, T. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38979 · Cited by 36
Characteristics of Patients Undergoing Bariatric Surgery in Canada
Padwal, R. S. (2005) · Obesity Research · doi:10.1038/oby.2005.253 · Cited by 27
Self-citationMcRobbie, H. J., Hájek, P., Peerbux, S., Kahan, B. C., Eldridge, S. M., Trépel, D., Parrott, S., Griffiths, C., Snuggs, S. J., & Smith, K. M. (2016) · Health Technology Assessment · doi:10.3310/hta20790 · Cited by 32
Influence of weight discrimination on weight loss goals and self‐selected weight loss interventions
Sharma, S., Wharton, S., Forhan, M. A., & Kuk, J. L. (2011) · Clinical Obesity · doi:10.1111/j.1758-8111.2011.00028.x · Cited by 28
Obesity Management Interventions: A Review of the Evidence
Yaskin, J. C., Toner, R. W., & Goldfarb, N. I. (2009) · Population Health Management · doi:10.1089/pop.2008.0049 · Cited by 32
Dieting Frequency in Obese Patients With Binge Eating Disorder: Behavioral and Metabolic Correlates
Roehrig, M., Masheb, R. M., White, M. A., & Grilo, C. M. (2009) · Obesity · doi:10.1038/oby.2008.600 · Cited by 27
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes
Nelson, R. H., & Miles, J. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.14.2483 · Cited by 26
Medical Therapy for Obesity—Current Status and Future Hopes
Bray, G. A. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.013 · Cited by 27
Medical Management of Obesity and its Complications
Caterson, I. D. (2009) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v38n1p22 · Cited by 37
Jindal, A., Brietzke, S., & Sowers, J. R. (2012) · Cardiorenal Medicine · doi:10.1159/000343803 · Cited by 28
Safety profile of orlistat: results of a prescription-event monitoring study
Acharya, N. V., Wilton, L., & Shakir, S. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803323 · Cited by 28
O efeito da sibutramina na perda de peso de adolescentes obesos
Franco, R. R. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2013.tde-12042013-102419 · Cited by 25
Neuropharmacology of human appetite expression
Halford, J. C. G., & Harrold, J. A. (2008) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.20 · Cited by 24
Medications for Weight Reduction
Bray, G. A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.08.004 · Cited by 25
Phentermine cardiovascular safety
Rothman, R. B., & Hendricks, E. J. (2009) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2009.07.014 · Cited by 25
The use of commitment techniques to support weight loss maintenance in obese adolescents
Kulendran, M., King, D., Schmidtke, K. A., Curtis, C., Gately, P., Darzi, A. W., & Vlaev, I. (2016) · Psychology and Health · doi:10.1080/08870446.2016.1204452 · Cited by 23
Current and novel approaches to the drug therapy of obesity
Chaput, J., & Tremblay, A. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0186-z · Cited by 26
Childhood obesity: an overview of laboratory medicine, exercise and microbiome
Scudiero, O., Pero, R., Ranieri, A., Terracciano, D., Fimiani, F., Cesaro, A., Gentile, L., Leggiero, E., Laneri, S., Moscarella, E., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0789 · Cited by 33
Stubbs, R. J., Brogelli, D. J., Pallister, C., Whybrow, S., Avery, A., & Lavin, J. (2012) · Clinical Obesity · doi:10.1111/j.1758-8111.2012.00040.x · Cited by 24
Khajuria, V., Arora, E., Tandon, V., Sharma, A., Mahajan, A., Gillani, Z., & Choudhary, N. (2015) · Perspectives in Clinical Research · doi:10.4103/2229-3485.148812 · Cited by 21
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Cruz‐Hernandez, C., de Oliveira, M. C., Pescia, G., Moulin, J., Masserey‐Elmelegy, I., Dionisi, F., & Destaillats, F. (2010) · Nutrition Research · doi:10.1016/j.nutres.2009.12.001 · Cited by 22
Vascular disease: obesity and excess weight as modulators of risk
Rao, G. H. R., Thethi, I., & Fareed, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.43 · Cited by 23
Public Health Response to the Obesity Epidemic: Too Soon or Too Late?
Byers, T., & Sedjo, R. L. (2007) · Journal of Nutrition · doi:10.1093/jn/137.2.488 · Cited by 22
Kampe, J., Brown, W. A., Stefanidis, A., Dixon, J. B., & Oldfield, B. J. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9751-0 · Cited by 19
Haddock, C. K., Poston, W. S. C., Foreyt, J. P., DiBartolomeo, J. J., & Warner, P. (2008) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/bf03327609 · Cited by 19
Mathus-Vliegen, E. M. H. (2006) · Obesity Surgery · doi:10.1381/096089206778870003 · Cited by 20
Therapeutic Role of Phytomedicines on Obesity: Importance of Herbal Pancreatic lipase Inhibitors
Singh, S., & Kanwar, S. S. (2013) · Cited by 23
The Challenge of Obesity Treatment: A Review of Approved Drugs and New Therapeutic Targets
Bonamichi, B. D. S. F., Parente, E. B., dos Santos, R. B., Beltzhoover, R., Lee, J., & Salles, J. E. N. (2018) · Journal of Obesity & Eating Disorders · doi:10.21767/2471-8203.100034 · Cited by 20
Uso de drogas antiobesidade entre estudantes universitários
Martins, M. D. C. D. C. E., Filho, M. D. D. S., Moura, F. S., de Carvalho, J., Müller, M., Neves, R. V., Mousinho, P. C., & Lima, I. P. (2011) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302011000500017 · Cited by 39
Osei‐Assibey, G., Adi, Y., Kyrou, I., Kumar, S., & Matyka, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01346.x · Cited by 18
The Long‐Term Management of Obesity with Continuing Pharmacotherapy
Frank, A. (2004) · Obesity Research · doi:10.1038/oby.2004.226 · Cited by 18
Is Acetazolamide Similar to Topiramate for Reversal of Antipsychotic-Induced Weight Gain?
Schneiderhan, M. E., & Marvin, R. G. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31813e65b7 · Cited by 18
Osei-Assibey, G., & Boachie, C. (2011) · Public Health Nutrition · doi:10.1017/s1368980011001121 · Cited by 20
Brissette, C., Jenkins, A. L., Choleva, L., & Vuksan, V. V. V. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.183 · Cited by 24
Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
Wharton, S., Lee, J., & Christensen, R. A. G. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s141571 · Cited by 20
New agents in development for the management of obesity
Vincent, R. P., & le Roux, C. W. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01558.x · Cited by 18
Ebine, N., Demonty, I., Jia, X., & Jones, P. J. H. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803191 · Cited by 18
Saad, B., Zaid, H., Shanak, S., & Kadan, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-54102-0_3 · Cited by 17
Summers, C., & Curtis, K. (2020) · JMIR Diabetes · doi:10.2196/15030 · Cited by 18
Management of type 2 diabetes in the obese patient: current concerns and emerging therapies
Krentz, A. J. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x219661 · Cited by 17
Al-Tahami, B. A. M., Ismail, A. A. A.-S., Sanip, Z., Zurkurnai, Y., Shihabudin, T. M. T., Singh, T. S. P., & Rasool, A. H. G. (2017) · Journal of Nippon Medical School · doi:10.1272/jnms.84.125 · Cited by 18
Kushner, R. F. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.01.004 · Cited by 19
The Challenge of Treating Obesity: The Endocannabinoid System as a Potential Target
Isoldi, K. K., & Aronne, L. J. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2008.02.019 · Cited by 21
Surgical Management of Obesity in Patients with Morbid Obesity and Nonalcoholic Fatty Liver Disease
Dixon, J. B. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.011 · Cited by 16
O’Brien, P. E., DeWitt, D. E., Laurie, C., Brennan, L., Wentworth, J. M., Anderson, M. L., O’Dea, K., Dean, F., Smith, A. I., & Dalton, D. P. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1733-4 · Cited by 16
The Effectiveness of Screening for Obesity in Primary Care: Weighing the Evidence
Wilson, A. R., & McAlpine, D. D. (2006) · Medical Care Research and Review · doi:10.1177/1077558706290942 · Cited by 16
Wadikar, D. D., & Premavalli, K. S. (2012) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2010.514757 · Cited by 19
New medications for obesity management: changing the landscape of obesity treatment
Boulghassoul-Pietrzykowska, N., Franceschelli, J., & Still, C. D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000433059.78485.fa · Cited by 16
Klein, S., & Romijn, J. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00036-8 · Cited by 16
Park, S., Park, J.-S., Cheon, C., Yang, Y., An, C., Jang, B.-H., Song, Y.-K., Go, H.-Y., Lee, J. A., Shin, Y. C., et al. (2012) · Trials · doi:10.1186/1745-6215-13-33 · Cited by 15
Hájek, P., Humphrey, K., & McRobbie, H. J. (2009) · Patient Education and Counseling · doi:10.1016/j.pec.2009.10.017 · Cited by 14
O sistema endocanabinóide: nova perspectiva no controle de fatores de risco cardiometabólico
Francischetti, E. A., & de Abreu, V. G. (2006) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2006001700023 · Cited by 30
Does rimonabant pull its weight for type 2 diabetes?
Cleland, S. J., & Sattar, N. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69572-x · Cited by 14
Koutroumanidou, E., & Pagonopoulou, O. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2475 · Cited by 17
Paxman, J. R., Hall, A. C., Harden, C. J., O'Keeffe, J., & Simper, T. N. (2011) · Nutrition Research · doi:10.1016/j.nutres.2011.03.015 · Cited by 13
Use of anti-obesity drugs among college students
Martins, M. D. C. D. C. E., Filho, M. D. D. S., Moura, F. S., de Carvalho, J., Müller, M., Neves, R. V., Mousinho, P. C., & Lima, I. P. (2011) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(11)70113-8 · Cited by 13
Role of the Endocannabinoid System in Abdominal Obesity and the Implications for Cardiovascular Risk
Rosenson, R. S. (2009) · Cardiology · doi:10.1159/000230691 · Cited by 14
Martínez, J. J. G., Ruiz, F. A., & Candil, S. D. (2006) · British Journal Of Nutrition · doi:10.1017/bjn20061899 · Cited by 13
Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome
Kahal, H., Atkin, S. L., & Sathyapalan, T. (2010) · Journal of Obesity · doi:10.1155/2011/402052 · Cited by 14
Review: Drug treatments for obesity: where are we heading and how do we get there?
Sonnenberg, G. E., Matfin, G., & Reinhardt, R. R. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070030301 · Cited by 13
Change in abdominal obesity and risk of coronary calcification
Sabour, S., Grobbee, D. E., Prokop, M., van der Schouw, Y. T., & Bots, M. L. (2011) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2009.099002 · Cited by 12
Delahanty, L. M., Riggs, M. R., Klioze, S. S., Chew, R. D., England, R. D., & DIGENIO, A. G. (2016) · Obesity Science & Practice · doi:10.1002/osp4.57 · Cited by 12
Obesity: an epidemic of the 21st century.
Islam, N. (2005) · PubMed · Cited by 12
Medications for Weight Reduction
Bray, G. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.009 · Cited by 12
Toxicity and Safety Concerns in Orlistat Therapy for Obesity: A Critical Evaluation
Nwobodo, N. N. (2015) · Asian journal of biomedical and pharmaceutical sciences · doi:10.15272/ajbps.v5i47.725 · Cited by 14
Farah, D., & Fonseca, M. C. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.005 · Cited by 11
Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.12.010 · Cited by 11
Rimonabant: New data and emerging experience
Wright, S. M., Dikkers, C., & Aronne, L. J. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0011-5 · Cited by 13
Padwal, R. S. (2005) · Obesity Research · doi:10.1038/oby.2005.234 · Cited by 13
Self-citationEfficacy of chalcone and xanthine derivatives on lipase inhibition: A systematic review
Tam, D. N. H., Mostafa, E. M., Tu, V. L., Rashidy, A. I., Matenoglou, E., Kassem, M. A. M., Soa, D. T., Bayumi, A., Emam, H. E., Tran, L., et al. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13626 · Cited by 11
Zhou, Y. T., Wei, Q., Fan, Q., & Wan, C. (2010) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826070903574220 · Cited by 10
Hill, G. R., Ashton, J., & Harrison‐Woolrych, M. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1447 · Cited by 10
Metadata
- Authors
- Padwal, R., Li, S. K., & Lau, D. C. W.
- Affiliations
- University of Alberta Hospital (CA)
- University of Calgary (CA)
- Corresponding author
- Padwal, R
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2003-09-16
- Volume
- 27
- Issue
- 12
- Pages
- 1437-1446
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W2135749311
- Cited by
- 348
- References
- 57
- Citations by year
- 2026: 1 · 2025: 11 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 8 · 2018: 8 · 2017: 9 · 2016: 8 · 2015: 11 · 2014: 13 · 2013: 21 · 2012: 20
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- anti-obesity drugs, orlistat, sibutramine, obesity, overweight, weight loss, long-term efficacy, drug safety, gastrointestinal adverse effects, blood pressure, cardiovascular risk
- MeSH terms
- Orlistat, Cyclobutanes, Humans, Lactones, Obesity, Randomized Controlled Trials as Topic, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.